Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin + Gemcitabine in R/R PTCL
NCT03496779Phase 2Completed
- Sponsor
- LYSARC
- Start
- Apr 2018
- Primary completion
- Jan 2020
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of brentuximab vedotin in peripheral T-cell lymphoma (PTCL), sponsored by LYSARC. Started Apr 2018; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT03496779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03496779.